Conformationally restricted analogs of baclofen (2), i.e., 5, 6, and their enantiomers ent-5, and ent-6 , the conformations of which were restricted by introducing a cyclopropane ring, were designed as potential GABA B receptor ligands. Reaction of (R)-epichlorohydrin [(R)-7] and (4-chlorophenyl)acetonitrile in the presence of NaNH 2 in benzene/tetrahydrofuran gave chiral cyclopropane derivatives 11 and 12, which were then converted into the target compounds 5 and 6, respectively. Their corresponding enantiomers, ent-5 and ent-6, were also synthesized starting from (S )-epichlorohydrin [(S )-7].
g-Aminobutyric acid (GABA, 1) is an inhibitory neurotransmitter. Its two major receptor subtypes, GABA A and GABA B receptors, have been identified based on electrophysiological 1) and binding 2) studies. Although several specific agonists or antagonists at GABA A receptor sites have been developed, 3, 4) 3-(4-chlorophenyl)-4-aminobutyric acid (baclofen, 2) 5) is the only clinically useful selective GABA B agonists. Therefore, additional efficient GABA B receptor agonists and antagonists are eagerly awaited. Phaclofen (3) 6) and 2-hydroxy-saclofen (4) 7) have been reported to be selective GABA B antagonists in vitro. However, these have not been used to investigate the pharmacology of GABA B antagonists in vivo, perhaps due to their inability to penetrate the blood brain barrier. 8, 9) Conformationally restricted analogs of a lead compound often improve the specific binding affinity for the receptor.
10)
Conformationally restricted analogs have usually been designed and synthesized by introducing cyclic moieties, which are often rather bulky, into lead compounds. As a consequence, their chemical and physical properties are often changed. From this perspective, restricting the conformation of a key functional group by introducing a small cyclopropane ring should be effective. For instance, Ohfune and co-workers have developed useful probes for excitatory amino acid receptors by restricting the conformation of glutamate by introducing a cyclopropane structure into the molecule.
11) We also recently developed potent N-methyl-D-aspartic acid (NMDA) receptor antagonists by a novel conformation-restricting method based on the structural feature of a cyclopropane ring. 12) In the present study, we designed conformationally restricted analogs of (R)-and (S)-baclofen, i.e., 5, 6, and their enantiomers ent -5, and ent-6 , as shown in Chart 1, to identify efficient agonists and/or antagonists for the GABA B receptor. The conformations of these compounds are locked into folded or extended forms by introducing a cyclopropane structure to the molecule. 13) In this report, we describe the synthesis and binding affinity of these conformationally restricted analogs to GABA B receptor.
Chemistry The synthesis of optically active cyclopropane derivatives has been extensively studied in recent years because of their biological importance. 14) We recently reported the efficient synthesis of optically active phenylcyclopropane lactones, starting from chiral epichlorohydrins. 12a-c) This procedure using (R)-or (S)-epichlorohydrin as a synthon is one of the most useful methods for preparing chiral cyclopropanes; phenylcyclopropane products of high optical purity can be obtained on a large scale from chiral epichlorohydrins, which are stable and readily available in high optical purity. In this reaction, the carbon nucleophile attacks with high regioselectively at the 3-position of epichlorohydrin, and (1S,2R)-lactone 10 is obtained from (R)-7 while the corresponding enantiomer, (1R,2S)-lactone ent-10, is obtained from (S)-7 (Chart 2). We planned to synthesize the target compounds in this study by using this reaction from chiral epichlorohydrins.
We investigated the reaction of (R)-7 and a carbanion derived from (4-chlorophenyl)acetonitrile under various conditions. The best results were obtained when the reaction was carried out with NaNH 2 as a base in benzene/tetrahydrofuran (THF) at room temperature; (1S,2R)-lactone 11 with 93% e.e. 15) was isolated in 68% yield after alkaline hydrolysis of the nitrile group followed by treatment with HCl (Chart 3). In this reaction, the corresponding trans-product 12 was also obtained as a minor product. 16) Ammonolysis of 11 with NH 3 /MeOH followed by reduction of the resulting amide with BH 3 · THF gave aminoalcohol 15. After the amino function was protected with a tertbutyloxycarbonyl (Boc) group, it was oxidized with pyridinium dichromate (PDC) in the presence of 4A molecular sieves to give lactam 17. Following removal of the Boc group with trifluoroacetic acid (TFA), the resulting N-free lactam was heated under reflux in HCl to give the conformationally restricted analog 5 as a hydrochloride.
The scheme for preparing the trans-analog 6 is shown in Chart 4. Successive treatment of crude 12 with Ac 2 O in pyridine, ClCO 2 Oiso-Bu, and NH 3 in CHCl 3 gave trans-acetate 18 in a pure form in 10% yield from (R)-7. After the acetyl group of 18 was removed, it was converted into the target conformationally restricted analog 6 17) by a procedure similar to that for synthesizing the cis-analog 5 described above.
The corresponding enantiomers, ent-5, and ent-6 were also synthesized starting from (ϩ)-epichlorohydrin [(S) -5] . Effect on Brain GABA B Receptors The binding of these compounds to GABA B receptor in rat brain was measured in the presence of isoguvacine (40 mM) to block GABA A receptors. 18) None of the four conformationally restricted analogs of baclofen synthesized in this study significantly competed with [
3 H]GABA for GABA B receptors at concentrations of 10 nM to 100 mM in crude synaptic membranes of rat brain. In the same experiment, (Ϯ)-baclofen (10 nM-10 mM), (R)-baclofen (10 nM-10 mM) and (S)-baclofen (10 mM-1 mM) competed with [ (meanϮS.E., nϭ3) to displace 50% of control specific binding were 0.36Ϯ0.16, 0.30Ϯ0.12, and 526Ϯ68 mM, respectively.
These results suggest that the three-dimensional structures of compounds 5, 6, ent-5, and ent-6 may be different from the conformation of baclofen at the binding site of GABA B receptor.
Experimental
Melting points were measured on a Yanagimoto MP-3 micromelting point apparatus and are uncorrected. NMR spectra were recorded with a JEOL FX-270, a GSX-400, or a Bruker ARX-500 spectrometer with tetramethylsilane as an internal standard. Mass spectra were recorded with a JEOL JMS-HX110 spectrometer. Chemical shifts are reported in parts per million (d), and signals are expressed as s (singlet), d (doublet), t (triplet), m (multiplet), or br (broad), and coupling constants are indicated in Hz. Thin-layer chromatography was done on Merck precoated plates 60F 254 . Chromatography was conducted with Merck Silica gel 9025. Reactions were done under argon.
(1S,5R)-1-(4-Chlorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one (11) and (1S,2S )-1-(4-Chlorophenyl)-2-hydroxymethylcyclopropanecarboxylic Acid (12) A solution of (4-chlorophenyl)acetonitrile (25.0 g, 323 mmol) in benzene/THF (10 : 1. 200 ml) was added slowly to a suspension of NaNH 2 (25.8 g, 660 mmol) in benzene/THF (10 : 1. 1.25 l) at 0°C, and the mixture was stirred at room temperature for 2 h. To the resulting mixture, a solution of (R)-epichlorohydrin [(R)-7, 25.3 ml, 323 mmol] in benzene/THF (10 : 1. 200 ml) was added at 0°C, and the whole was stirred at room temperature for 3 h. After EtOH (100 ml) was added, the solvent was evaporated. EtOH (200 ml) and 3 N KOH (70 ml) were added to the residue, and the mixture was heated under reflux for 12 h and then acidified with 12 N HCl at 0°C (pH of the mixture was about 1). The resulting mixture was evaporated, and EtOAc and saturated aqueous NaHCO 3 were added and partitioned. The organic layer separated was washed with brine, dried (Na 2 SO 4 ), evaporated, and purified by column chromatography (silica gel; hexane/EtOAc, 5 : 2 then hexane/EtOAc/AcOH, 50 : 50 : 1) to give 11 (oil, 45.9 g, 68%) and crude 12 (oil, 10.2 g), the structure of which was confirmed as below. 11: The optical purity was determined by a chiral HPLC (Chiralcel-OJ, 0.46ϫ25 cm, Daicel Chemical Industries Co., Ltd.; hexane/iso-PrOH, 7 : 3, 0. 4 4.35; Cl, 16.99. Found: C, 63.51; H, 4.55; Cl, 16.94 .
(1S,2R)-1-(4-Chlorophenyl)-2-hydroxymethylcyclopropane Carboxamide (14) Ammonia gas was bubbled into a solution of 11 (44.9 g, 215 mmol) in MeOH (1000 ml) at Ϫ78°C for 20 min. After the resulting solution was allowed to warm to room temperature, the solvent was evaporated. , 5.36; N, 6.21. Found: C, 58.51; H, 5.38; N, 6.18. (1R,2S )-2-Aminomethyl-2-(4-chlorophenyl)cyclopropylmethanol (15) A solution of BH 3 · THF (1.03 M in THF, 400 ml, 412 mmol) was added slowly to a solution of 14 (39.6 g, 176 mmol) in THF (900 ml) at 0°C, and then the mixture was heated under reflux for 7 h. After the mixture was cooled to room temperature, MeOH (100 ml) was added, and the solvent was evaporated. EtOAc and 3 N HCl were added to the residue and partitioned. The organic layer separated was washed with brine, dried (Na 2 SO 4 ), evaporated, and purified by column chromatography (silica gel; CHCl 3 /MeOH/ 28% NH 4 3.39 (1H, dd, Jϭ11.3, 11.8 Hz) , 3.52 (1H, d, Jϭ12.6 Hz), 3.56 (1H, s), 4.21 (1H, dd, Jϭ5.4, 11.8 Hz), 7.36 (2H, d, Jϭ8.8 Hz), 7.42 (2H, d, Jϭ8.7 Hz Cl, 11.52; N, 4.49. Found: C, 62.59; H, 5.98; Cl, 11.56; N, 4.62 .
[(1S,2R)-2-Carboxy-1-(4-chlorophenyl)cyclopropylmethyl]ammonium Cloride (5) A mixture of 17 (154 mg, 0.50 mmol) and TFA (578 ml, 7.5 mmol) in CH 2 Cl 2 (1.0 ml) was stirred at room temperature for 8 h. After the solvent was evaporated, CHCl 3 and saturated aqueous NaHCO 3 were added, and the resulting mixture was partitioned. The organic layer separated was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; CHCl 3 /MeOH, 12 : 1) to give yellow solids, which were heated in 6 N HCl (5 ml H-NMR (500 MHz, CD 3 OD) 1.46 (1H, dd, Jϭ5.2, 5.7 Hz), 1.56 (1H, dd, Jϭ5.2, 8.6 Hz), 2.60 (1H, dd, Jϭ5.7, 8.6 Hz), 3.45 (1H, d, Jϭ13.5 Hz), 3.53 (1H, d, Jϭ13.5 Hz), 7.32 (2H, d, Jϭ8.5 Hz), 7.35 (2H, d, Jϭ8.5 Hz) . , 5.24; N, 5.13. Found: C, 48.19; H, 4.83; N, 5.05 .
Methyl (1S,2S)-1-(4-Chlorophenyl)-2-hydroxymethylcyclopropanecarboxylate (13)
A mixture of 12 (113 mg, 0.50 mmol) and TMSCHN 2 (2 M in hexane, 0.30 ml. 0.60 mmol) in benzene (3 ml) and MeOH (2 ml) was stirred at room temperature for 18 h. After addition of AcOH (1 M in benzene, 100 ml), the solvent was evaporated. The residue was partitioned between EtOAc and water, and the organic layer separated was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/EtOAc, 2 : 1) to give 13 (oil, 63 mg, 67%): the optical purity was determined as 94% e.e. by a chiral HPLC (Chiralcel-OJ, 0.46ϫ25 cm, Daicel Chemical Industries Co., Ltd.; hexane/isoPrOH, 3 : 1, 0.5 ml/min; 230 nm).
[a] D 26 ϭϪ7.69°(cϭ0.586, CHCl 3 ). 1 H-NMR (270 MHz, CDCl 3 ) 1.22 (1H, dd, Jϭ4.5, 6.7 Hz), 1.74 (1H, dd, Jϭ4.5, 9.3 Hz) , 2.24-2.13 (1H, m), 3.15 (1H, dd, Jϭ8.2, 11.6 Hz), 3.49 (1H, s), 3.49 (1H, dd, Jϭ5.7, 11.6 Hz), 3.63 (3H, s), m) . and Ac 2 O (5.1 ml, 54 mmol) in pyridine (300 ml) was stirred at room temperature for 19 h. After MeOH was added, the solvent was evaporated, and the residue was partitioned between EtOAc and water. The organic layer separated was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; CHCl 3 /MeOH, 15 : 1) to give yellow oil. The oil was dissolved in CHCl 3 (300 ml), to which ClCO 2 iso-Bu (7.0 ml, 54 mmol) and Et 3 N (9.4 ml, 68 mmol) were added at Ϫ15°C, and the resulting solution was stirred at the same temperature for 2 h. NH 3 gas was bubbled into the resulting solution at Ϫ15°C for 10 min, and then the mixture was allowed to warm to room temperature. After water was added, the mixture was partitioned, and the organic layer separated was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/EtOAc, 1 : 1) to give 18 (yellow solid, 9.3 g, 10% from (R)- 1H, dd, Jϭ4.3, 6.6 Hz), 1.74 (1H, dd, Jϭ4.3, 9.3 Hz), m), 3.48 (1H, dd, Jϭ8.4, 12.0 Hz), 3.96 (1H, dd, Jϭ6.0, 12.0 Hz), 5.25 (1H, br s), 5.45 (1H, br s), 7.34 (2H, d, Jϭ8.5 Hz), 7.38 (2H, d, Jϭ8.5 Hz) . 13 ClNO 3 : C, 58.32; H, 5.27; Cl, 13.24; N, 5.23. Found: C, 58.30; H, 5.29; Cl, 13.39; N, 5.21 .
(1S,2S )-1-(4-Chlorophenyl)-2-hydroxymethylcyclopropanecarboxamide (19) A mixture of 18 (9.3 g, 32 mmol) and K 2 CO 3 (5.7 g, 54 mmol) in MeOH (80 ml) was stirred at room temperature for 5 h. After neutralization with aqueous KHSO 4 (1 M), CHCl 3 and saturated aqueous NaHCO 3 were added to the resulting mixture, and then the whole was partitioned. The organic layer separated was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; CHCl 3 3.06 (1H, dd, Jϭ8.4, 11.2 Hz), 3.34 (1H, dd, Jϭ6.0, 11.2 Hz), 3.39 (2H, br s), 7.28 (2H, d, Jϭ8.4 Hz), 7.31 (2H, d, Jϭ8.4 Hz) . 13 ClNO 3 : C, 61.63; H, 7.11; Cl, 11.37; N, 4.49. Found: C, 61.22; H, 7.10; Cl, 11.33; N, 4.35. (
1S,2S )-2-(4-Chlorophenyl)-2-[N-(tert-butoxycarbonyl]aminomethyl]-cyclopropanecarboxylic Acid (22)
A mixture of 21 (529 mg, 1,7 mmol), PDC (1.28 g, 3.4 mmol) , and molecular sieves 4Å (powder, 1.7 g) in CH 2 Cl 2 (17 ml) was stirred at room temperature for 3 h. After Et 2 O was added, the resulting mixture was filtered with Celite, and the filtrate was evaporated. To the residue, NaClO 2 (561 mg, 6.0 mmol), NaH 2 PO 4 (296 mg, 1.7 mmol), water (3.4 ml), and acetone (13.6 ml) were added, and the mixture was stirred at room temperature for 9.5 h. The solvent was evaporated, and the residue was partitioned between CHCl 3 and water. The organic layer separated was washed with brine, dried (Na 2 SO 4 ), and evaporated. 3.17 (1H, dd, Jϭ6.7, 13.4 Hz), 3.41 (1H, dd, Jϭ4.9, 13.4 Hz) 
